Pda Technical Report 82 Jun 2026

For products in development, TR 82 provides guidance to formulation scientists:

If a product exhibits LER, TR 82 recommends testing multiple dilution factors of the product in the BET. Often, a 1:10 or 1:100 dilution in LAL Reagent Water (LRW) disrupts the masking agents (e.g., diluting out polysorbate or chelators), allowing full endotoxin recovery. If recovery improves with dilution, LER is present.

: Adding dispersants or using specific reagents like the ENDO-RS methodology to restore recovery. pda technical report 82

Titled "Controlled Temperature Chain: Technical Requirements for Controlled Temperature Chain (CTC) Operations," this document has become the gold standard for managing the cold chain. This article explores the depths of PDA TR 82, examining its origins, its core principles, and how it revolutionizes the way the pharmaceutical industry approaches the stability and distribution of sensitive products.

The report offers specific guidelines for conducting "hold-time" studies to prove that endotoxin can be reliably detected throughout a product's shelf life or manufacturing process. Recommended parameters include: For products in development, TR 82 provides guidance

Just to get you started — here are the of PDA TR 82:

The report addresses the mechanisms, detection, and mitigation of LER in biopharmaceuticals, vaccines, cell therapies, and complex small-molecule formulations. : Adding dispersants or using specific reagents like

Download the full PDA TR 82 document (PDA members get free access; non-members can purchase). Turn to Table 3.1 – "Checklist for LER Evaluation." Complete that checklist for every parenteral product in your portfolio within the next 90 days.